ClinicalTrials.gg
RecruitingNCT05607693Updated May 15, 2023

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

A Phase 1 interventional study of SHR3680 tablets in Castration-Resistant Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing rezvilutamide in Prostatic Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. rezvilutamide · Prostatic Neoplasms.

Planned enrollment
11th of 18
52 · median 98
Started
2023
with 5 others
Phase 1
4 of 18
1 open now
Primary completion
2024-11
later than 1 of 10 live
Registered
10th of 18
by date
Lead sponsor
9 of 18
Jiangsu HengRui Medicine Co., Ltd.

Among the 18 studies testing rezvilutamide in Prostatic Neoplasms, this one is the 11th largest by planned enrollment, is one of 6 that started in 2023, is one of 4 in phase 1, reaches primary completion later than 1 of the 10 other live ones, and was the 10th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 18 studies testing rezvilutamide in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About rezvilutamide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rezvilutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).

03

Conditions studied

  • Castration-Resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male between 18 years to 75 years of age;
  2. (ECOG) performance status score of 0 or 1;
  3. Expected survival of at least 6 months;
  4. or cytologically confirmed adenocarcinoma of the prostate without indication of neuroendocrine or small cell features; nonmetastatic castration-resistant prostate cancer (NM-CRPC) or castration-resistant prostate cancer (mCRPC) ;
  5. Be surgically or medically castrated and if treated with a gonadotropin releasing hormone analog (ie, patient who has not undergone bilateral orchiectomy), then this therapy must have been initiated at least 4 weeks prior to Day 1 and must be continued throughout the study;
  6. Castrated level of testosterone at screening (≦ 50 ng/dL or 1.73 nmol/L);
  7. Organ function level must meet the following requirements (blood transfusion or hematopoietic growth factor therapy was not received within 2 weeks before blood test):

    • ANC≧1.5×109/L;
    • ≧80×109/L;
    • ≧90 g/L;
    • ≦1.5×;
    • and AST≦2.5×ULN;
    • BUN and Cr≦1.5×ULN;
    • ≧60ml/min/1.73m2;
  8. 12-lead : heart rate ≥ 50 beats/min, PR interval within 110-220 ms (including both ends), corrected according to Fridericia 's criteria (QTcF) \< 470 msec. (LVEF) ≥ 50% by echocardiography;
  9. Able to complete the study as required by the protocol;
  10. Sign the before the trial, and fully understand the trial content, process and possible adverse reactions.

Exclusion criteria

Exclusion Criteria:

  1. of any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, androgen receptor antagonists, CYP-17 inhibitors, 5α-reductase inhibitors, estrogen, progesterone drugs, etc.) to the of the first dose of this study drug is \< 4 weeks;
  2. Plan to receive any other anti-tumor therapy during the treatment phase in this trial;
  3. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 4 weeks;
  4. Known ;
  5. history of epilepsy, or past medical history of disease that can induce seizures (including history, cerebral stroke (except cerebral ischemic lesions only found in imaging test), brain trauma with disturbance of consciousness requiring hospitalization) within 12 months before the first dose of the study drug;
  6. past medical history of the following diseases within 6 months before screening: myocardial infarction, severe/unstable angina, class II-IV cardiac insufficiency, ≥ Grade 2 sustained arrhythmia (graded based on 5.0), heart failure, grade II-III atrioventricular block, complete left bundle branch block, atrial fibrillation of any grade, coronary/peripheral artery bypass graft or stenting, cerebrovascular accident (including transient ischemic attack), pulmonary embolism, deep vein thrombosis;
  7. Inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of multiple other factors affecting drug administration and absorption;
  8. Patients with active or infection (HBV copy number ≥ 104 copies/mL, HCV copy number ≥ 103 copies/mL);
  9. Patients with immunodeficiency disease history (including test positive, other acquired or congenital immunodeficiency diseases) or organ transplantation history;
  10. Patients who are unwilling to take protocol-specified measures throughout the study treatment period and within 3 months after the last dose;
  11. History of significant , intolerance, or allergy to any drug compound or known allergy to SHR3680 or the ;
  12. Excessive smoking (≥ 5 cigarettes/day) within 6 months before screening or smoking within 48 h before the first dose, or positive at nicotine screening test, and can't abstain from smoking during the study; History of drug abuse, positive at drug abuse screening, or history of any drug use in the past 6 months;
  13. History of alcoholism or regular alcohol consumption within 6 months before screening, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol or 45 mL of spirits with 40% alcohol or 150 mL of wine with 12% alcohol) or drinking within 48 h before the first dose, or positive at alcohol breath test on the day of admission, or unable to abstain during the study;
  14. Subjects who took any vitamins, health products or herbal medicine within 14 days before dosing;
  15. Subjects who took any beverage or food containing grapefruit, xanthine, caffeine, or alcohol within 48 hours before dosing; strenuous exercise; or other factors which affect drug absorption, distribution, metabolism, excretion, etc;
  16. Abnormal coagulation function ( > 1.5 or prothrombin time (PT) > + 4 seconds or APTT > 1.5 ULN), bleeding tendency or on thrombolytic therapy;
  17. Patients with implantable pacemaker and automatic implantable cardioverter defibrillator;
  18. Personal or family history of long syndrome;
  19. Use of Medications that prolong QT/QTc interval or with risk of torsades de pointes (TdP) within 7 days prior administration of study drug;
  20. Significant history or clinical manifestation of concomitant diseases or other situations that put serious hazards to the patient' s safety, or affect the patient 's completion of the study, as determined by the Investigator.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    SHR3680

    Drug: SHR3680 tablets

Interventions

  • Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.

06

What researchers measure

Primary outcomes

  1. Delta QTc Fridericia (QTcF)

    Mean change from baseline in QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake.

    Time frame: Day -1 and Day 1 and Day 17

  2. Concentration-delta QTcF relationship

    Relationship between SHR3680 plasma concentration and delta QTcF based on linear-mixed effect model.

    Time frame: Day -1 and Day 1 and Day 17

Secondary outcomes

  1. Electrocardiographic parameters Delta PR

    A change from time-matched baseline measurements in PR interval will be determined on Day -1, Day 1 and Day 17.

    Time frame: Day -1 and Day 1 and Day 17

  2. Electrocardiographic parameters Delta RR

    A change from time-matched baseline measurements in RR interval will be determined on Day -1, Day 1 and Day 17.

    Time frame: Day -1 and Day 1 and Day 17

  3. Electrocardiographic parameters Delta QRS

    A change from time-matched baseline measurements in QRS interval will be determined on Day -1, Day 1 and Day 17.

    Time frame: Day -1 and Day 1 and Day 17

  4. Electrocardiographic parameters Delta QTc Bazett (QTcB)

    Mean change from baseline in QTcB as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake.

    Time frame: Day -1 and Day 1 and Day 17

  5. Electrocardiographic parameters T-wave morphology

    Number and percentage of participants with changes from baseline

    Time frame: Day -1 and Day 1 and Day 17

  6. Electrocardiographic parameters U-wave morphology

    Number and percentage of participants with changes from baseline

    Time frame: Day -1 and Day 1 and Day 17

  7. Incidence and severity of AE/SAE/AESI (rated based on CTCAE v5.0)

    Participants will be monitored for safety during the Screening and Treatment Phases, and up to 30 days after the last dose of study drug. From the end of treatment phase onward collection of AE will be limited to Grade 3 or higher, all SAE and AESI from the remainder of the study.

    Time frame: Day-1, Day 1 to Day 18

  8. Pharmacokinetic parameter area under the plasma drug concentration-time curve (AUC) from time 0 to 24 hours

    Time frame: Day 1-2 and Day 17-18

  9. Pharmacokinetic parameter maximum concentration observed (Cmax)

    Time frame: Day 1-2 and Day 17-18

  10. Pharmacokinetic parameter time to reach Cmax (tmax)

    Time frame: Day 1-2 and Day 17-18

  11. Pharmacokinetic parameter minimum observed plasma concentration at steady-state (Cmin,ss)

    Time frame: Cmin,ss will only be collected on Day 17

  12. Pharmacokinetic parameter accumulation ratio(Rac)

    Time frame: Day 1-2 and Day 17-18

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital of Tianjin
    Tianjin, Tianjin 300000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2024, 18 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 18 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2022
First posted
Nov 7, 2022
StartActual
Apr 26, 2023
Primary completionEst.
Nov 5, 2024
CompletionEst.
Nov 5, 2024
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05607693
Responsible party
Sponsor
First posted
Nov 7, 2022
Start date
Apr 26, 2023
Primary completion
Nov 5, 2024 (estimated)
Completion
Nov 5, 2024 (estimated)
Last update
May 15, 2023

Study contacts

YIKE WANG, Pharm.D
Contact
yike.wang@hengrui.com
+86-134-0862-8814
Shaorong Li, Ph.D
Contact
shaorong.li@hengrui.com
+86-180-0162-4511

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezvilutamide

Start the discussion